Literature DB >> 36178663

Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.

Dane Rucker1, Jacob Joseph2,3.   

Abstract

PURPOSE OF REVIEW: Heart failure with preserved ejection fraction (HFpEF) imposes a significant burden on society and healthcare. The lack in efficacious therapies is likely due to the significant heterogeneity of HFpEF. In this review, we define various phenotypes based on underlying comorbidities or etiologies, discuss phenotypes arrived at by novel methods, and explore therapeutic targets. RECENT
FINDINGS: A few studies have used machine learning methods to uncover sub-phenotypes within HFpEF in an unbiased manner based on clinical features, echocardiographic findings, and biomarker levels. We synthesized the literature and propose three broad phenotypes: (1) young, with few comorbidities, usually obese and with low natriuretic peptide levels, (2) obese with substantive cardiometabolic burden and comorbidities and impaired ventricular relaxation, (3) old, multimorbid, with high rates of atrial fibrillation, renal and coronary artery disease, chronic obstructive pulmonary disease, and left ventricular hypertrophy. We also propose potential therapeutic strategies for these phenotypes.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Keywords:  Biomarkers; Heart failure with preserved ejection fraction; Imaging; Machine learning; Phenotypes; Precision medicine

Year:  2022        PMID: 36178663     DOI: 10.1007/s11897-022-00582-x

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  109 in total

Review 1.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

2.  Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.

Authors:  Jordana B Cohen; Sarah J Schrauben; Lei Zhao; Michael D Basso; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Zhaoqing Wang; Priyanka T Bhattacharya; Diana A Chirinos; Stuart Prenner; Payman Zamani; Dietmar A Seiffert; Bruce D Car; David A Gordon; Kenneth Margulies; Thomas Cappola; Julio A Chirinos
Journal:  JACC Heart Fail       Date:  2020-01-08       Impact factor: 12.035

Review 3.  Treatment of cardiac transthyretin amyloidosis: an update.

Authors:  Michele Emdin; Alberto Aimo; Claudio Rapezzi; Marianna Fontana; Federico Perfetto; Petar M Seferović; Andrea Barison; Vincenzo Castiglione; Giuseppe Vergaro; Alberto Giannoni; Claudio Passino; Giampaolo Merlini
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

4.  Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades.

Authors:  Ramachandran S Vasan; Vanessa Xanthakis; Asya Lyass; Charlotte Andersson; Connie Tsao; Susan Cheng; Jayashri Aragam; Emelia J Benjamin; Martin G Larson
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-05

Review 5.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

6.  Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance.

Authors:  Patricia P Chang; Lisa M Wruck; Eyal Shahar; Joseph S Rossi; Laura R Loehr; Stuart D Russell; Sunil K Agarwal; Suma H Konety; Carlos J Rodriguez; Wayne D Rosamond
Journal:  Circulation       Date:  2018-03-08       Impact factor: 29.690

Review 7.  Economic Issues in Heart Failure in the United States.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Yekaterina Opsha; Alexander T Sandhu; Nancy K Sweitzer; Haider J Warraich
Journal:  J Card Fail       Date:  2022-01-24       Impact factor: 6.592

8.  Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.

Authors:  David P Kao; James D Lewsey; Inder S Anand; Barry M Massie; Michael R Zile; Peter E Carson; Robert S McKelvie; Michel Komajda; John J V McMurray; JoAnn Lindenfeld
Journal:  Eur J Heart Fail       Date:  2015-08-06       Impact factor: 15.534

9.  Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.

Authors:  João Pedro Ferreira; Marco Metra; Ify Mordi; John Gregson; Jozine M Ter Maaten; Jasper Tromp; Stefan D Anker; Kenneth Dickstein; Hans L Hillege; Leong L Ng; Dirk J van Veldhuisen; Chim C Lang; Adriaan A Voors; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2018-10-19       Impact factor: 15.534

Review 10.  The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials.

Authors:  Silvia Oghina; Wulfran Bougouin; Mélanie Bézard; Mounira Kharoubi; Michel Komajda; Alain Cohen-Solal; Alexandre Mebazaa; Thibaud Damy; Diane Bodez
Journal:  JACC Heart Fail       Date:  2021-02-03       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.